ReVision now anticipates initiating early-stage human clinical trials of its Occular BCI in blind volunteers in 2027.

ReVision Implant announced today that it received FDA breakthrough device designation for its Occular visual cortical prosthesis.

About 30 million people around the world have grown legally blind due to retinal diseases. The EPI-RET project has sought for a technical solution for the past twelve years to help these patients.

SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ:EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...

Neural computation scientists have created a software system that is hoped to improve the function of retinal implants significantly: With the aid of the software, the visual prosthesis "learns" to ...

The Intracortical Visual Prosthesis (ICVP), an implant that bypasses the retina and optic nerves to connect directly to the brain's visual cortex, has been successfully surgically implanted in the ...

Retinitis pigmentosa and age-related macular degeneration are two significant causes of severe visual dysfunction. In both, the retinal photoreceptors degenerate, preventing successful conversion of ...

A retinal prosthesis system can safely, effectively, and reliably restore enough visual function to patients with late-stage retinitis pigmentosa to improve object detection and overall well-being, ...

The public markets have proven a rocky path for Second Sight Medical Products ($EYES) since strong initial investor enthusiasm peaked just after its November IPO. But ...

SYLMAR, Calif.--(BUSINESS WIRE)--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics that are ...

Implanting intraocular lenses (IOLs) after cataract surgery in infants is neither beneficial nor detrimental to long-term visual outcomes, according to a study published in JAMA Ophthalmology. In this ...